Safety and antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in persons with HIV
2021; Lippincott Williams & Wilkins; Volume: 35; Issue: 14 Linguagem: Inglês
10.1097/qad.0000000000003017
ISSN1473-5571
AutoresJake A. Ruddy, Brian J. Boyarsky, Justin R. Bailey, Andrew H. Karaba, Jacqueline Garonzik‐Wang, Dorry L. Segev, Christine M. Durand, William A. Werbel,
Tópico(s)Animal Virus Infections Studies
ResumoThis study of SARS-CoV-2 mRNA vaccination in 14 persons with HIV (PWH) demonstrated uniformly high anti-SARS-CoV-2 receptor binding domain (RBD) antibody titres after two doses, despite varied titres after a single dose. The majority of vaccine reactions were mild and no adverse events occurred.
Referência(s)